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Abstract
Evidence accumulates for associations between hypertensive pregnancy disorders and increased cardiovascular risk later. The
main goal of this study was to explore shared biomarkers representing common pathogenic pathways between heart failure
with preserved ejection fraction (HFpEF) and pre-eclampsia where these biomarkers might be potentially eligible for cardio-
vascular risk stratiﬁcation in women after hypertensive pregnancy disorders. We sought for blood markers in women with
diastolic dysfunction in a ﬁrst literature search, and through a second search, we investigated whether these same biochemical
markers were present in pre-eclampsia.This systematic review and meta-analysis presents two subsequent systematic
searches in PubMed and EMBASE. Search I yielded 3014 studies on biomarkers discriminating women with HFpEF from female
controls, of which 13 studies on 11 biochemical markers were included. Cases had HFpEF, and controls had no heart failure.
The second search was for studies discriminating women with pre-eclampsia from women with non-hypertensive pregnancies
with at least one of the biomarkers found in Search I. Search II yielded 1869 studies, of which 51 studies on seven biomarkers
were included in meta-analyses and 79 studies on 12 biomarkers in systematic review.Eleven biological markers differentiated
women with diastolic dysfunction from controls, of which the following 10 markers differentiated women with pre-eclampsia
from controls as well: C-reactive protein, HDL, insulin, fatty acid-binding protein 4, brain natriuretic peptide, N terminal pro
brain natriuretic peptide, adrenomedullin, mid-region pro adrenomedullin, cardiac troponin I, and cancer antigen 125.Our
study supports the hypothesis that HFpEF in women shares a common pathogenic background with pre-eclampsia. The
biomarkers representing inﬂammatory state, disturbances in myocardial function/structure, and unfavourable lipid metabo-
lism may possibly be eligible for future prognostic tools.
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Introduction
Cardiovascular disease (CVD) is the main cause of mortality in
the Western world, and its prevalence worldwide is growing.
The diagnosis of CVD is often delayed in women due to differ-
ences in clinical presentation and underlying pathophysiology
compared to the male standard.1–4 From post-menopausal
age on, more women than men suffer from CVD.4,5 Heart
failure with preserved ejection fraction (HFpEF) is a common
female manifestation of CVD at advanced age and forms a
signiﬁcant and growing public health burden. Diagnosis of
HFpEF is challenging because of its long asymptomatic
course.6–8 Recent literature suggests biomarkers of inﬂamma-
tion, myocyte stress, and extracellular remodelling as
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possible screening instruments speciﬁcally for HFpEF.9,10
Early identiﬁcation and treatment of women in high-risk
groups could prevent this debilitating disease later in life.
Women with a history of a hypertensive pregnancy
disorder, including pre-eclampsia, have an elevated cardiovas-
cular risk.11–13 In recent decades, pregnancy has been hypoth-
esized as a cardiovascular stress test revealing elevated
susceptibility for CVD at a relatively young age.13 During
pre-eclampsia, the clinical threshold for CVD is exceeded,
and the biomarker proﬁle in pre-eclamptic pregnancies may
thus be an early reﬂection of the biochemical imbalance in
CVD at advanced age. In consistency with this theory, recent
literature has shown an increase of established CVD bio-
markers in women during and after pre-eclampsia.14–16 The
incidence of HFpEF is higher in women than in men; therefore,
we attend to the possibility of a shared pathogenic back-
ground with pre-eclampsia.
It has been hypothesized that women with hypertensive
pregnancy disorders would be eligible for CVD preventive
healthcare programmes. Currently, evidence is lacking on
how to accurately map these women’s cardiovascular status,
and little is known about the common pathogenicmechanisms
in pre-eclampsia and CVD.12 Broader knowledge on the shared
pathogenic pathways may provide biochemical markers with
high sensitivity and speciﬁcity for the detection of (subclinical)
CVD, and in particular HFpEF, in affected high-risk women.
The aim of this systematic literature review and meta-
analysis was therefore to explore what is currently known
in literature about shared biomarkers identifying both
women with early signs of HFpEF and women with pre-
eclampsia to unravel a shared pathogenic background and re-
veal biomarkers with possible future potential for HFpEF
screening after pre-eclampsia.
Methods
So as to ﬁnd corresponding biomarkers for diastolic heart fail-
ure (DHF) in women and pre-eclampsia, two subsequent,
closely linked searches were performed according to Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines. Complete search queries are presented
in the Supporting Information.
Search I: diastolic heart failure
Deﬁnitions
Deﬁnition of HFpEF was described in the guidelines of the
European Society of Cardiology.17 Brieﬂy, two characteristics
had to be apparent at echocardiography: ﬁrstly, evidence of
left ventricular diastolic dysfunction; tissue Doppler E/E’
>15 or 15> E/E’ >8 and conﬁrmation by blood ﬂow Doppler
or mitral valve/pulmonary veins, echo measures of left
ventricular mass index/left atrial volume index, or
electrocardiographically conﬁrmed atrial ﬁbrillation. Sec-
ondly, left ventricle systolic dysfunction had to be
normal/mildly abnormal with left ventricular ejection fraction
>50% and left ventricular end-diastolic volume index
<97 mL/m2.
Search strategy
A search in PubMed and EMBASE was performed from incep-
tion on 13 July 2015 that consisted of the following terms and
a wide variety of their synonyms: DHF or preserved ejection
fraction and biomarker.
Study selection
Eligible for inclusion in Search I were case-control and cohort
studies comparing biomarker levels in women with DHF vs.
women without heart failure or studies correlating biomarker
levels with diastolic function through regression analysis.
Studies were included if performed exclusively in women or
if data were completely stratiﬁed by gender. Studies investi-
gating patient groups with structural heart diseases or co-
morbidities unrelated to metabolic syndrome or heart failure
were excluded.
Included studies were processed by a scoring form devel-
oped by three reviewers (L. A., A. B., and C. d. G.). Data ex-
traction and scoring per article for disease deﬁnition, study
design, patient and control group characteristics, biomarkers,
blood sample collection and analysis was performed by L. A.
and veriﬁed by A. B. The same reviewers independently
scored bias risk and applicability concern for each included
study according to the QUADAS-2 quality assessment tool
for primary diagnostic accuracy studies.18 Any fundamental
inconsistencies were discussed with C. d. G.
Outcomes of interest
Primary outcomes were biomarkers in blood separating
women with HFpEF from women without heart failure. The
result of Search I, a list of biomarkers signiﬁcantly different
(P < 0.05) in HFpEF vs. controls, was taken along to Search
II where primary outcomes were biomarkers in pre-
eclampsia.
Search II: pre-eclampsia
Deﬁnitions
Pre-eclampsia was deﬁned according to International Society
for the Study of Hypertension in pregnancy criteria as de
novo hypertension of ≥140/90 mm Hg in combination with
proteinuria >0.3 g/24 h after 20 weeks gestational age.19
To prevent unnecessary exclusion of older studies, pre-
eclampsia could also be deﬁned as a rise of systolic blood
pressure >30 mm Hg or diastolic blood pressure >15 mm Hg
with proteinuria in women with no history of chronic hyper-
tension.20 Early-onset, or severe, pre-eclampsia was deﬁned
as delivery before 34 weeks of gestation or blood pressure
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≥160/110 mm Hg or proteinuria >5 g/24 h. Late-onset, or
mild, pre-eclampsia implied giving birth from 37th week of
gestation.
Search strategy
We performed a search in PubMed and EMBASE from incep-
tion on 1 September 2015. The search strategy contained two
components: (1) biomarkers for HFpEF in women from
Searches I and II) pre-eclampsia. So as to fully explore the
pathway of mid-region pro ADM (MRproADM), studies on
its fully modulated version adrenomedullin (ADM) were also
included in this review, leaving a total of 12 markers for
Search II. Thus, the following terms with their synonyms
and abbreviations were used: troponin I or brain natriuretic
peptide (BNP) or N-terminal pro-BNP (NTproBNP) or high-
density lipoprotein (HDL) or cancer antigen 125 (CA-125) or
carcino-embryonic antigen (CEA) or C-reactive protein or
ADM or MRproADM or fatty acid-binding protein 4 (FABP4)
or insulin or glucose and pre-eclampsia.
Study selection
Case-control and cohort studies comparing pre-eclamptic
with non-hypertensive pregnancies were eligible for inclusion
in Search II. Biomarker levels had to be measured during
pregnancy, and it had to be ≥1 of the biomarkers from Search
I. To gain only data on pre-eclampsia, the studies that did not
separate pregnancy-induced hypertension (without protein-
uria) from pre-eclampsia and studies failing to exclude
women with chronic hypertension were not incorporated in
this review. Studies presenting their data in the right mea-
surement unit and using mean with standard
deviation/standard error to describe biomarker levels were
eligible for meta-analysis.
Data extraction and determination of study characteristics,
bias, and applicability was performed as in Search I.
Outcomes of interest
Primary outcomes were biomarkers differentiating pre-
eclamptic from non-hypertensive pregnancies. Where possi-
ble, we performed subgroup analyses for biomarker levels
in ‘early-onset/severe’, ‘late-onset/mild’ pre-eclampsia and
in different pregnancy trimesters (most subgroup analyses
are presented in the Supporting Information).
Data synthesis
Review Manager 5.3 (Cochrane Collaboration, Oxford, UK)
was used for meta-analyses. All data were continuous, and
only raw numbers were used from the studies. Biomarkers’
measurement units were converted according to the
International System of Units (SI). A standardized mean dif-
ference was chosen for inconvertible measurement units.
Weighting of studies was carried out by inverse variance so
that larger studies would be given more weight than smaller
ones and all analyses were performed with a randomized
effect model because heterogeneity was to be expected.
Heterogeneity was determined by I2. GraphPad Prism 6
(GraphPad Software, San Diego California, USA) was used to
visualize data and compare the group of means plus medians
together through unpaired t-test or one-way ANOVA.
Conﬁdence intervals throughout this whole review were set
at 95%, and for all effect estimates, statistical signiﬁcance
level was P < 0.05.
Results
Literature identiﬁcation and study quality
The process of study inclusion and exclusion in systematic re-
view and meta-analysis is depicted in Figure 1.
Search I Thirteen studies on biomarkers in HFpEF in women
were included for systematic review, and we had
insufﬁcient results for meta-analysis. The included
studies described 11 HFpEF markers in total: BNP
NTproBNP, cardiac troponin I (c-Tn1), MRproADM,
c-reactive protein, HDL, insulin, plasma glucose,
FABP4, CA-125, and CEA. For reasons mentioned
earlier, we added ADM, leaving 12 biomarkers for
Search II.
Search II The search for biomarkers in HFpEF (Search I) and
pre-eclampsia yielded 79 studies for systematic re-
view of which 51 (on BNP, ADM, C-reactive protein,
HDL, insulin, plasma glucose, and CA-125) were
applicable for meta-analyses. We present most
subgroup analyses on biomarkers in ‘early onset/
severe’ or ‘late onset/mild’ in the Supporting
Information.
Study characteristics
Characteristics of all included studies are presented in the
Supporting Information, Tables S1 (DHF) and S2 (PE). Included
studies were published between 1996 and 2015. With the
QUADAS-2 score for study quality and applicability, 8.6% of all
included studies got assigned a high and 28.6% an unclear bias
risk. Furthermore, applicability concern was high in 28.5% and
unclear in 33.5%. QUADAS-2 subsections are further visualized
in the Supporting Information Figure S2 in Data in Brief.
Cardiovascular risk markers in pre-eclampsia
C-reactive protein
Thirty-two studies in total reported on C-reactive protein
levels,21–52 of which 17 were applicable for
meta-analysis.21–23,29–34,37–39,41,42,47,49,50 A signiﬁcantly
higher C-reactive protein was found in women with pre-
eclampsia than in non-hypertensive controls (Figure 2), and
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this correlation was stronger in severe than in mild pre-
eclampsia (Figure 3).
High-density lipoprotein
Twenty-seven studies reported on HDL levels,32,37,41,44,53–74 of
which 24 studies could be included in a meta-
analysis.32,37,41,53–72 HDL level was lower in pre-eclampsia
than in controls (mean difference 6.29 mmol/L; 95%CI
9.742.85; P = 0.0003) with the strongest effect in sub-
group analysis for severe pre-eclampsia vs. controls (Figure 4).
Insulin, plasma glucose, and fatty acid-binding
protein 4
Five studies reported on insulin levels.37,45,55,62,75 Three met
the requirements for a meta-analysis,37,55,75 revealing higher
insulin levels in pre-eclampsia than in controls with mean dif-
ference 1.31 μU/mL; 95%CI 0.93–1.70; P < 0.00001. Two
studies reporting in median (IQR) revealed similar slightly el-
evated insulin levels in pre-eclampsia.45,62
Six studies reported on plasma glucose levels,
32,45,62,65,75,76 of which ﬁve were applicable for meta-analysis
with 115 pre-eclampsia cases vs. 329 controls.32,62,65,75,76
Overall, a non-signiﬁcantly elevated glucose level was seen
in pre-eclampsia vs. controls.
One study reported on FABP4 levels in pre-eclampsia
compared with controls and found statistically higher FABP4
levels in pre-eclampsia vs. non-hypertensive pregnancy.77
Myocardial failure markers in pre-eclampsia
Brain natriuretic peptide and N-terminal pro-BNP
Seven studies reported on BNP levels,78–84 of which three
were applicable for a meta-analysis (Figure 5).78–80
In all seven studies and in meta-analysis, BNP levels were
signiﬁcantly higher in pre-eclampsia than in controls.
Subgroup analyses revealed higher BNP levels for severe
pre-eclampsia vs. control as well as severe vs. mild pre-
eclampsia, P-values 0.0023 and 0.0391, respectively.
Three studies reporting on NTproBNP described
elevated levels in pre-eclampsia vs. controls with
P = 0.0103 (Figure 6),85–87 with insufﬁcient studies for
meta-analyses.
Adrenomedullin, mid-region pro ADM, and cardiac
troponin I
Seven studies reported on ADM levels,88–94 of which ﬁve met
the requirements for meta-analysis.88–91,94 However, because
these worked with inconvertible measurement units, two sep-
aratemeta-analyseswith inconsistent results were carried out.
The ﬁrst showed lower ADM in pre-eclampsia;mean difference
5.60 pmol/L; 95%CI14.76–3.55; P= 0.23.88,91,94 The second
meta-analysis showed higher ADM in pre-eclampsia; mean
difference 41.44 pg/mL; 95%CI 12.58–70.31; P = 0.005.89,90
The two studies inapplicable for meta-analysis showed higher
levels of ADM in pre-eclampsia vs. control.92,93
Figure 1 Study selection process Searches I and II. CHT, chronic hypertension; HFpEF, heart failure with preserved ejection fraction; PE, pre-eclampsia;
PIH, pregnancy-induced hypertension.
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Two studies on MRproADM described signiﬁcantly higher
levels in pre-eclampsia vs. controls.95,96
Two studies on c-Tn1 described elevated levels in pre-
eclampsia compared with controls,97,98 of which only one
with statistically signiﬁcant result.97
Tumour angiogenesis markers in pre-eclampsia
Cancer antigen 125 and carcino-embryonic antigen
Three studies reported on CA-125 levels in pre-eclampsia vs.
controls,26,99,100 of which two studies described signiﬁcantly
Figure 3 C-reactive protein, mild vs. severe pre-eclampsia.
Figure 4 High-density lipoprotein, severe pre-eclampsia vs. controls.
Figure 2 C-reactive protein, pre-eclampsia vs. controls.
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lower CA-125 levels in PE99,26 and one did not show signiﬁ-
cantly different CA-125 levels between pre-eclampsia and
controls.100
No studies exploring the CEA levels in pre-eclamptic vs.
non-hypertensive pregnancies were found in our systematic
literature search.
Discussion
Main ﬁndings
This systematic review and meta-analysis presents 10 bio-
markers that both discriminate women with HFpEF from
controls and discriminate women with pre-eclampsia from
healthy pregnant women (C-reactive protein, HDL, insulin,
FABP4, BNP, NTproBNP, ADM, MRproADM, c-Tn1, and CA-
125) and thereby gives insight into a possibly common path-
ophysiology. We found a shared range of biomarkers which
support the hypothesis that cardiovascular decompensation
during a challenging phase such as pregnancy might be con-
sidered an early reﬂection of a metabolically and biochemi-
cally predisposed system for CVD. These markers may
inspire future research on HFpEF screening programs after
pre-eclampsia, and inﬂammatory markers may therein play
a particularly important role.
Strengths and limitations
One of the strongest points of this review is that we analysed
only the data on women. In recent decades has become clear
how men and women differ in many manifestations of CVD
including clinical picture, age of onset and diagnostic possibil-
ities.1,3,5 Because this is a relatively recent insight, we cur-
rently lack female-only data in for example cardiovascular
risk management.
This broad literature search had a unique design
transcending medical specialties: we composed a biomarker
proﬁle for women with HFpEF from all current literature
and subsequently tested the existence of these same markers
in women with pre-eclampsia; to our knowledge, this was the
ﬁrst systematic review in such direction. Furthermore, search
and selection criteria, data extraction forms, and applicability
scoring methods were developed by multiple investigators af-
ter careful consideration.
Selection bias was avoided as much as possible. Firstly,
Search I had a wide design with no speciﬁc biomarkers in
the search string. This allowed all possible biomarkers on
HFpEF in literature to be selected for the review. Secondly,
all studies from the DHF search that met the criteria ‘DHF’
and ‘biomarker’ were screened full text to see whether data
for women were separately displayed. Thus, even if the au-
thors’ main focus was not on female biomarkers for DHF, as
long as they displayed the data separately, the article could
still be included in our review. Unfortunately, many HFpEF
studies failed to present female data separately and had to
be excluded after full text exploration. It is thus important
for future studies on CVD to report by gender.
This review had some limitations regarding the characteris-
tics of included studies. For instance, studies presenting data
in median (IQR) were not compatible for meta-analysis. More-
over, not all studies could be taken into the same (meta-)anal-
yses because of heterogeneity regarding measurement units,
stratiﬁcation methods, and ways of data presentation. Pri-
mary study outcomes especially varied greatly between DHF
Figure 5 Brain-natriuretic peptide, pre-eclampsia vs. controls.
Figure 6 N-terminal pro-brain natriuretic peptide, pre-eclampsia vs.
controls.
Biomarkers for HFpEF and preeclampsia 93
ESC Heart Failure 2017; 4: 88–98
DOI: 10.1002/ehf2.12129
studies, which stood in the way of performing a meta-analysis
on the biomarker levels in DHF. If meta-analyses were applica-
ble, they were often characterized by high heterogeneity. This
might be partly explained by a methodological limitation be-
cause we included studies with older, and thus slightly differ-
ent, deﬁnitions of pre-eclampsia. Another partial explanation
for heterogeneity, which is hard to get a grip on, is the fact
that most studies failed to report on pre-eclampsia disease
status on moment of blood sampling. Lastly, some studies
gave insufﬁcient information on study design including
inter-/intra assay variance, fasting state of the participants,
maternal age, and gestational age at delivery.
There were also limitations regarding the design of
current review. Firstly, this review only focused on bio-
markers analysed during pregnancy to extrapolate markers
that embody an evidently unbalanced cardiovascular
system. Our study design was unable to determine whether
(shortly) after hypertensive pregnancy the cardiovascular
system returns to normal state or whether the biomarker
levels remain elevated. Secondly, we focused on pre-
eclampsia and not on pregnancy-induced hypertension with-
out proteinuria, which is thought to be a different disease
entity and might therefore yield a different view on
cardiovascular risk prediction after hypertensive pregnancy.
Thirdly, the markers we investigated are speciﬁc for HFpEF
in women, which only partly cover one CVD. Despite the
fact that HFpEF is one of the main CVD entities in women
and it has a long subclinical course, it would be interesting
to investigate whether other typical female CVDs, such as
cerebrovascular accident, thrombo-embolism, and myocar-
dial infarction at advanced age, are linked to pre-eclampsia
through the same pathophysiological pathways as we
found. Finally, this review does not cover women who have
such serious cardiovascular malfunction that they fail to
become pregnant in the ﬁrst place and thus, by their
nature, never develop pre-eclampsia.
Implications and future research
Current systematic review and meta-analysis presents repre-
sentative biomarkers from several pathophysiological path-
ways in HFpEF as well as pre-eclampsia. This information
might in future be implemented in prediction of cardiovascu-
lar risk in women with a history of pre-eclampsia through
pathway activity screenings.
C-reactive protein appeared the biomarker best able to dis-
criminate between all pre-eclampsia vs. controls, sampling tri-
mesters, and pre-eclampsia severity subgroups. These ﬁndings
accentuate the role inﬂammation plays in both female HFpEF
and pre-eclampsia and suggest the possible use of C-reactive
protein in cardiovascular risk screening in pregnancies compli-
cated by hypertension. The inﬂammatory component of
HFpEF has been mentioned previously,10,101 with for example
IL-6, TNF-α, interleukin receptors, and pentraxin 3 as potential
HFpEF biomarkers.10,102–105 To our knowledge, gender-
speciﬁc data on this topic are currently lacking; thus with our
women-only designed search, we probably overlooked a num-
ber of studies on inﬂammatory markers in HFpEF.
Brain natriuretic peptide and NTproBNP measurements
have already been implemented in diagnostic criteria for
HFpEF17. We found BNP and NTproBNP to be elevated in
pre-eclampsia, which suggests a possible role for these bio-
markers in screening for HFpEF speciﬁcally after PE. The abso-
lute difference in BNP levels for pre-eclampsia vs. controls is
smaller than for HFpEF vs. controls, suggesting a more subtle
role for BNP in pre-eclampsia than in HFpEF. Nevertheless, el-
evated BNP and NTproBNP levels in pre-eclampsia indicate
similar cardiac overstretching in pre-eclampsia as in DHF. In
broader perspective, BNP levels in heart failure with reduced
ejection fraction (HFrEF) usually exceed levels in HFpEF;111,112
thus, BNP elevation in pre-eclampsia suggests that the dis-
ease gives higher risk to systolic heart failure or a mixed heart
failure image. Elevated c-Tn1 levels in pre-eclampsia are
directly suggestive of cardiomyocyte damage, whereas ele-
vated ADM, MRproADM, BNP, and NTproBNP levels in pre-
eclampsia suggest a compensatory mode in hypertensive
pregnancy to protect the cardiovascular system from any
further damage.
Despite the fact that only one study reported on higher
FABP4 in pre-eclampsia, it might still be an interesting biomarker
for HFpEF after PE, because recent literature describes this adi-
pocyte fatty acid transporter as a key player between metabolic
syndrome, inﬂammation, atherosclerosis, and CVD.106
Cancer antigen 125, a serosal glycoprotein antigen inter alia
found on female reproductive tract epithelia, is a marker used
for detection and clinical follow-up of several malignant and
non-malignant serosal pathologies.107,108 In two separate arti-
cles, it has been suggested that it may also function as a marker
in both our entities of interest: pre-eclampsia99 and heart fail-
ure,109 our results support this view. The pathophysiology for
CA-125 elevation in both pre-eclampsia and heart failure is dif-
ﬁcult to address because a great variety of cell types produces
CA-125.110 The low speciﬁcity of CA-125 calls out for further re-
search on the source of secretion in pre-eclampsia and heart
failure before possible implementation in screening.
From this review, we can interpret that screening for HFpEF
in women with a history of pre-eclampsia would have to in-
clude multiple biomarkers representing a variety of pathogenic
pathways: ﬁrstly, because biomarker levels sometimes over-
lapped between cases and controls; and secondly, because nu-
merous pathophysiological processes appeared to play part in
both disease entities. So as to facilitate future screening within
the shared pathogenic pathways between pre-eclampsia and
HFpEF, longitudinal research is necessary to learn more about
the course of representative biomarker levels over time and in
relation to the developing clinical status before implementa-
tion into clinical practice would be possible.
94 L.J. Alma et al.
ESC Heart Failure 2017; 4: 88–98
DOI: 10.1002/ehf2.12129
Conclusions
Ten of the biomarkers differentiating women’s HFpEF from con-
trols, differentiated between pre-eclampsia and controls as
well: C-reactive protein, HDL, insulin, FABP4, BNP, NTproBNP,
ADM, MRproADM, c-Tn1, and CA-125. Our data suggest that
there is a shared biomarker proﬁle in HFpEF and pre-eclampsia
and support the hypothesis that these disease entities share an
intrinsic, vulnerable cardiovascular system with properties of
metabolic syndrome and an elevated inﬂammatory state. Pre-
eclampsia might be considered an early signal of underlying
CVD. With this review and meta-analysis, we present bio-
markers with potential for future implementation in cardiovas-
cular risk screening in women at risk after pre-eclampsia.
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